Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546714 | 0.88 | GCK (0.47) | MAOBMAOACYP1A2CYP1A1CYP19A1 | |
| SCHEMBL2265668 | 0.86 | MAOB (0.71) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL4674930 | 0.84 | MEN1 (0.70) | MAOBMAOACYP1A2MEN1KMT2A | |
| SCHEMBL763259 | 0.83 | LMNA (0.60) | MAOBMAOACYP1A2MEN1KMT2A | |
| SCHEMBL6394555 | 0.82 | ALDH1A1 (0.46) | MAOBMAOACYP1A2CYP1A1CYP19A1 | |
| SCHEMBL27314743 | 0.82 | MAOB (0.49) | MAOBMAOACYP1A2CYP1A1CYP19A1 | |
| SCHEMBL28441803 | 0.81 | CYP1A2 (0.73) | MAOBMAOACYP1A2CYP1A1CYP19A1 | |
| SCHEMBL578947 | 0.81 | MAOB (0.75) | MAOBMAOACYP1A2CYP1A1CYP19A1 | |
| SCHEMBL6661433 | 0.81 | MAOB (0.56) | MAOBMAOACYP1A2CYP1A1CYP19A1 | |
| SCHEMBL2516876 | 0.79 | APP (0.58) | MAOBMAOACYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230059087-A1 | CANNABIDIOL DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20230059087-A1 | CANNABIDIOL DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-4089084-A1 | CANNABIDIOL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| EP-4089084-A1 | CANNABIDIOL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021139741-A1 | CANNABIDIOL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 成都百裕制药股份有限公司 | 2021-07-15 | — | — | WO | disclosed |
| WO-2013095305-A1 | BODIPY STRUCTURE FLUORESCENCE PROBES FOR DIVERSE BIOLOGICAL APPLICATIONS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-06-27 | — | — | WO | disclosed |
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | MAOB 3032/4885MAOA 2512/4885CYP1A2 2267/4885 |
| US-20230059087-A1 | CANNABIDIOL DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF | CNR1, CNR2, UGT2B7 | MAOB 970/4885MAOA 1183/4885CYP1A2 20/4885 |
| US-20030158164-A1 | Novel antiandrogenic agent | NR5A1, CYP19A1, HSD17B11 | MAOB 3451/4885MAOA 3673/4885CYP1A2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.